{"preliminary_commentary":{"by_channel":{"bluesky_thread":3,"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05630183","nct_id":"NCT05630183","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05630183. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).","label":"Part 1: Combination (Safety Lead-in Phase)","type":"EXPERIMENTAL"},{"description":"Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).","label":"Part 2: Combination","type":"EXPERIMENTAL"},{"description":"Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).","label":"Part 2: Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-05","type":"ACTUAL"},"conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":81,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Botensilimab","otherNames":["AGEN1181"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-11","lead_sponsor":"Agenus Inc.","official_title":"A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival as Assessed by Investigator","timeFrame":"Up to 2 years"}],"references":[],"start_date":{"date":"2023-03-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT05630183"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05630183"}